Soolantra

Soolantra (ivermectin) Cream, 1% is a prescription-only topical medication specifically formulated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. It represents a significant advancement in dermatological therapy, offering a targeted mechanism of action that addresses the underlying inflammatory and parasitic components believed to contribute to this chronic facial skin condition. Its once-daily application provides a convenient treatment regimen that integrates seamlessly into a patient’s skincare routine, promoting both efficacy and adherence. Clinical studies have demonstrated its ability to significantly reduce lesion counts and improve overall patient quality of life.

Features

• Contains 1% ivermectin as the active pharmaceutical ingredient.
• Formulated in a light, non-comedogenic, oil-in-water cream base.
• Designed for topical application to the facial skin.
• Presented in a 30-gram pump dispenser for precise and hygienic dosing.
• Prescription-only medication, ensuring supervised use.
• Demonstrated anti-inflammatory and antiparasitic properties.

Benefits

• Targets the Root Cause: Ivermectin’s dual action reduces inflammation and demonstrates activity against Demodex folliculorum mites, which are implicated in the pathogenesis of rosacea.
• Significantly Reduces Lesion Count: Clinical trials show a substantial reduction in inflammatory lesions (papules and pustules) compared to vehicle (placebo) cream.
• Improves Skin Appearance: Leads to clearer skin with reduced redness and visible bumps, enhancing skin texture and tone.
• Convenient Once-Daily Dosing: A simple, single daily application supports long-term treatment adherence, which is critical for managing a chronic condition like rosacea.
• Generally Well-Tolerated: The topical formulation minimizes systemic exposure, resulting in a favorable safety profile with most adverse reactions being local and mild.
• Supports Skin Barrier Health: The cream base is designed to be moisturizing and is non-comedogenic, meaning it won’t clog pores or exacerbate the condition.

Common use

Soolantra is indicated specifically for the topical treatment of inflammatory lesions of rosacea. Rosacea is a common chronic dermatosis primarily affecting the central face (cheeks, nose, chin, and forehead). It is characterized by periods of flare-ups and remission. The inflammatory lesions Soolantra treats are the papules (small, solid bumps) and pustules (pus-filled bumps) associated with subtype 2 (papulopustular) rosacea. It is not indicated for the treatment of the persistent erythema (redness) or telangiectasias (visible blood vessels) also associated with the condition, though these may appear improved as inflammation subsides. It is used as a long-term control therapy, not an acute “spot treatment.”

Dosage and direction

For topical use only. Not for oral, ophthalmic, or intravaginal use.

• Apply a thin layer of Soolantra Cream to the affected areas of the face once daily.
• Use a pea-sized amount for each area of the face (forehead, chin, nose, each cheek). Avoid application to the eyes, eyelids, and lips.
• The cream should be applied to the entire affected area, not solely to individual lesions.
• Gently massage the cream into the skin until it is absorbed.
• Wash hands immediately after application.
• Cosmetics may be applied after the cream has dried.
• The duration of use should be as directed by a physician. Continuous use is often necessary for maintaining control of the condition.

Precautions

• For External Use Only: This product is for use on the skin only. If it comes into contact with the eyes, rinse thoroughly with water.
• Irritation: If severe skin irritation or hypersensitivity occurs, discontinue use and consult a physician.
• Pre-existing Skin Conditions: Use with caution in patients with other concurrent skin conditions or compromised skin barrier function (e.g., eczema, severe sunburn) as absorption may be increased and irritation may be more likely.
• Sun Exposure: While Soolantra itself is not a photosensitizer, patients with rosacea are generally advised to avoid excessive sun exposure, use broad-spectrum sunscreen, and wear protective clothing, as sunlight is a common trigger for flare-ups.
• Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether ivermectin is excreted in human milk following topical administration; caution should be exercised when administering to a nursing woman.

Contraindications

Soolantra is contraindicated in patients with a known hypersensitivity to ivermectin or to any of the excipients in the cream formulation.

Possible side effect

The most common adverse reactions reported in clinical trials were skin-related and generally mild to moderate in severity. These include:

• Skin burning sensation
• Skin irritation
• Pruritus (itching)
• Dry skin
• Contact dermatitis Systemic side effects are rare due to minimal absorption. However, in cases of compromised skin barrier or improper use, the following side effects associated with systemic ivermectin, though highly unlikely, could theoretically occur: dizziness, nausea, diarrhea, and hypotension.

Drug interaction

Formal drug interaction studies have not been conducted with topically applied Soolantra due to low systemic absorption. However, theoretically, because ivermectin is a substrate of the cytochrome P450 3A4 enzyme system, the concomitant use of potent enzyme inducers (e.g., rifampin, carbamazepine, phenytoin) or inhibitors (e.g., ketoconazole, ritonavir) could potentially affect the metabolism of any systemically absorbed ivermectin. The clinical significance of this for topical application is considered negligible.

Missed dose

If a dose is missed, it should be applied as soon as remembered on the same day. If the day has passed, skip the missed dose and resume the usual dosing schedule the next day. Do not apply a double dose to make up for a missed one.

Overdose

Topical overdose of Soolantra is unlikely to lead to life-threatening effects. Excessive application may lead to an increase in the frequency and severity of local adverse reactions (e.g., severe skin irritation, redness, burning). In the event of accidental ingestion, which would deliver a much higher dose, systemic effects similar to oral ivermectin overdose could occur. These may include gastrointestinal distress, dizziness, nausea, vomiting, and hypotension. In case of accidental ingestion, seek immediate medical attention or contact a Poison Control Center.

Storage

• Store at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).
• Keep the tube tightly closed and in the original carton to protect from light.
• Do not freeze.
• Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The full official prescribing information should be consulted before initiating treatment.

Reviews

• Clinical Trial Data: In pivotal Phase 3 studies, Soolantra demonstrated superior efficacy to vehicle cream. At week 12, significantly more patients achieved success on the Investigator’s Global Assessment scale, and a significantly greater reduction in inflammatory lesion counts was observed (mean reduction of 72-75% vs. 47-50% for vehicle).
• Dermatologist Endorsement: Soolantra is widely regarded by dermatologists as a first-line, evidence-based treatment for papulopustular rosacea due to its targeted mechanism, proven efficacy, and favorable tolerability profile. It is often praised for its ability to provide long-term control.
• Patient Feedback: Many patients report a noticeable reduction in bumps and redness within several weeks of starting treatment, with continued improvement over time. The once-daily application is frequently cited as a major benefit for compliance. Some users note an initial period of mild tingling or irritation that typically subsides. Individual results, as with all medications, can vary.